Distinguished in Atrial Fibrillation

Denis Angoulvant

CHRU De Tours
Tours, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Atrial Fibrillation
CHRU De Tours
Tours, FR 
OverviewLocationsClinical Research

Overview

Denis Angoulvant practices in Tours, France. Mr. Angoulvant is rated as a Distinguished expert by MediFind in the treatment of Atrial Fibrillation. His top areas of expertise are Heart Attack, Atrial Fibrillation, Stroke, Percutaneous Coronary Intervention (PCI), and Stent Placement.

His clinical research consists of co-authoring 194 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 31 articles in the study of Atrial Fibrillation.

Gender
Male

Locations

CHRU de Tours
Tours, 37000, France
Other Locations
Chambray-les-tours, 37170, France
CHU de Rennes
Rennes, 35000, France
Lyon, France
CHU de Caen
Caen, France
Nouzilly, 37380, France
Avenue De La République 37170 Chambray Lès Tours, Republique, 37170, France
Angers, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Impact on Quality of Life with Pulmonary RehAbilitation After Pulmonary EMBOlism: RAMBO Study
Impact on Quality of Life with Pulmonary RehAbilitation After Pulmonary EMBOlism: RAMBO Study
Enrollment Status: Recruiting
Publish Date: December 16, 2024
Intervention Type: Other
Study Phase: Not Applicable
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction
Enrollment Status: Completed
Publish Date: September 10, 2025
Intervention Type: Biological, Procedure, Device, Other
Study Phase: Not Applicable
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug
Study Phase: Phase 3
Myocardial Ischemia and Transfusion
Myocardial Ischemia and Transfusion
Enrollment Status: Completed
Publish Date: May 09, 2024
Intervention Type: Biological
Study Phase: Phase 3
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Direct Oral Anticoagulants
Study Phase: Phase 3
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
Enrollment Status: Terminated
Publish Date: October 19, 2022
Intervention Type: Drug
Study Drugs: Apixaban, Rivaroxaban, Heparin, VKA
Study Phase: Phase 3
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE
Enrollment Status: Completed
Publish Date: August 25, 2022
Intervention Type: Other
View 6 Less Clinical Trials

194 Total Publications

Towards Precision Secondary Prevention: Pharmacogenetic Insights from the Dalcetrapib-ADCY9 Pathway.
Towards Precision Secondary Prevention: Pharmacogenetic Insights from the Dalcetrapib-ADCY9 Pathway.
Journal: European journal of preventive cardiology
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Angoulvant's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 39 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile